These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1910052)

  • 1. Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
    Zazgornik J; Kuska J; Kokot F; Koch S; Van Peer A; Huang ML; Heykants J
    J Clin Pharmacol; 1991 Jul; 31(7):657-61. PubMed ID: 1910052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency.
    Zazgornik J; Huang ML; Van Peer A; Woestenborghs R; Heykants J; Stephen A
    J Clin Pharmacol; 1993 Dec; 33(12):1214-8. PubMed ID: 7907347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.
    Gaspari F; Viganò G; Locatelli M; Remuzzi G
    Am J Kidney Dis; 1988 Apr; 11(4):338-42. PubMed ID: 3354570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.
    Hanyok JJ; Chow MS; Kluger J; Izard MW
    J Clin Pharmacol; 1988 Sep; 28(9):831-6. PubMed ID: 3230150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.
    Singlas E; Taburet AM; Borsa Lebas F; Parent de Curzon O; Sobel A; Chauveau P; Viron B; al Khayat R; Poignet JL; Mignon F
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1519-24. PubMed ID: 1510449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease.
    Awni WM; Halstenson CE; Nayak RK; Opsahl JA; Desiraju RK; Minn FL; Matzke GR
    J Clin Pharmacol; 1995 Apr; 35(4):379-83. PubMed ID: 7650227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis.
    Gladziwa U; Bares R; Klotz U; Dakshinamurty KV; Ittel TH; Seiler KU; Sieberth HG
    Clin Pharmacol Ther; 1991 Dec; 50(6):673-81. PubMed ID: 1752111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofloxacin pharmacokinetics in renal failure.
    Fillastre JP; Leroy A; Humbert G
    Antimicrob Agents Chemother; 1987 Feb; 31(2):156-60. PubMed ID: 3471179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S; Boy M; Chow V; Chan G
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of loratadine in patients with renal insufficiency.
    Matzke GR; Halstenson CE; Opsahl JA; Hilbert J; Perentesis G; Radwanski E; Zampaglione N
    J Clin Pharmacol; 1990 Apr; 30(4):364-71. PubMed ID: 2140371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
    Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
    Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.
    Singh AB; Norris K; Modi N; Sinha-Hikim I; Shen R; Davidson T; Bhasin S
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2437-45. PubMed ID: 11397836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mepindolol in patients with chronic renal failure.
    Krause W; Kampf D; Fischer HC
    Eur J Clin Pharmacol; 1984; 27(4):429-33. PubMed ID: 6519149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.